Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by IFP Advisors Inc

IFP Advisors Inc trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 89.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,101 shares of the medical equipment provider's stock after selling 9,598 shares during the period. IFP Advisors Inc's holdings in Lantheus were worth $98,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the 4th quarter worth approximately $27,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the last quarter. World Investment Advisors LLC bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $74,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 6.1 %

Shares of NASDAQ:LNTH traded up $6.11 on Friday, reaching $106.34. The company had a trading volume of 1,369,851 shares, compared to its average volume of 921,738. Lantheus Holdings, Inc. has a 52-week low of $56.44 and a 52-week high of $126.89. The firm's 50 day simple moving average is $90.43 and its 200-day simple moving average is $96.80. The firm has a market capitalization of $7.28 billion, a PE ratio of 17.69 and a beta of 0.44.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective on the stock. Finally, Truist Financial raised their price objective on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $132.86.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.